Cullgen will have the option during the initial stages of clinical development to participate equally in the costs, profits and losses
Convergent action on AMR identified as an important area of intervention
Investment enables development of revolutionary multi-omic platform using super-resolution imaging technology for earlier disease detection and accelerated discovery of therapeutics
Total investments could reach €70 million, of which approximately 15% in R&D and 85% in capex, that would be deployed from 2026
Granules now has a total of 58 ANDA approvals from US FDA
Metoprolol Succinate ER Tablets are indicated for the treatment of hypertension in order to lower blood pressure.
Patent Term Extension is designed to restore some of the patent life lost during the regulatory review process for new drugs.
The application is in line with Innocan's strategy to expand the scope of its combined magnesium and cannabis topical solution
The randomised, multi-centre, evaluator blinded, parallel group, active controlled Phase 3 trial is being led by Lanhzou Biotechnique Development
Application being reviewed under the FDA Project Orbis framework, which enables concurrent reviews among US, Australia, Canada, Switzerland, Singapore and United Kingdom health authorities
Subscribe To Our Newsletter & Stay Updated
